51. An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity.
- Author
-
Borriello F, Poli V, Shrock E, Spreafico R, Liu X, Pishesha N, Carpenet C, Chou J, Di Gioia M, McGrath ME, Dillen CA, Barrett NA, Lacanfora L, Franco ME, Marongiu L, Iwakura Y, Pucci F, Kruppa MD, Ma Z, Lowman DW, Ensley HE, Nanishi E, Saito Y, O'Meara TR, Seo HS, Dhe-Paganon S, Dowling DJ, Frieman M, Elledge SJ, Levy O, Irvine DJ, Ploegh HL, Williams DL, and Zanoni I
- Subjects
- Aluminum Hydroxide chemistry, Animals, Antibodies, Neutralizing immunology, Antibody Specificity immunology, B-Lymphocytes immunology, COVID-19 immunology, COVID-19 prevention & control, COVID-19 virology, Chlorocebus aethiops, Epitopes immunology, Immunity, Innate, Immunization, Inflammation pathology, Interferons metabolism, Lectins, C-Type metabolism, Ligands, Lung immunology, Lung pathology, Lung virology, Lymph Nodes immunology, Lymph Nodes metabolism, Macrophages metabolism, Mice, Inbred C57BL, Paranasal Sinuses metabolism, Protein Subunits metabolism, Sialic Acid Binding Ig-like Lectin 1 metabolism, Solubility, Spike Glycoprotein, Coronavirus metabolism, T-Lymphocytes immunology, Transcription Factor RelB metabolism, Vero Cells, beta-Glucans metabolism, Mice, Adjuvants, Immunologic pharmacology, Antigens, Viral immunology, Candida albicans chemistry, Mannans immunology
- Abstract
Activation of the innate immune system via pattern recognition receptors (PRRs) is key to generate lasting adaptive immunity. PRRs detect unique chemical patterns associated with invading microorganisms, but whether and how the physical properties of PRR ligands influence the development of the immune response remains unknown. Through the study of fungal mannans, we show that the physical form of PRR ligands dictates the immune response. Soluble mannans are immunosilent in the periphery but elicit a potent pro-inflammatory response in the draining lymph node (dLN). By modulating the physical form of mannans, we developed a formulation that targets both the periphery and the dLN. When combined with viral glycoprotein antigens, this mannan formulation broadens epitope recognition, elicits potent antigen-specific neutralizing antibodies, and confers protection against viral infections of the lung. Thus, the physical properties of microbial ligands determine the outcome of the immune response and can be harnessed for vaccine development., Competing Interests: Declaration of interests F.B., E.N., T.R.O., I.Z., D.J.D., and O.L. are named inventors on invention disclosures and patents involving vaccine adjuvants. S.J.E. is a founder of TSCAN Therapeutics, ImmuneID, MAZE Therapeutics, and Mirimus. S.J.E. serves on the scientific advisory board of Homology Medicines, TSCAN Therapeutics, MAZE Therapetics, and XChem, and is an advisor for MPM, none of which impact this work. S.J.E. is an inventor on a patent application issued to the Brigham and Women’s Hospital (US20160320406A) that covers the use of the VirScan library to identify pathogen antibodies in blood. The other authors declare no commercial or financial conflict of interest., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF